25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis

被引:175
作者
Soilu-Hänninen, M
Airas, L
Mononen, I
Heikkilä, A
Viljanen, M
Hänninen, A
机构
[1] Univ Turku, Medicity Res Lab, FIN-20520 Turku, Finland
[2] Turku Univ Hosp, Cent Lab, FIN-20521 Turku, Finland
[3] Univ Turku, Dept Neurol, FIN-20521 Turku, Finland
[4] Univ Turku, Dept Med Microbiol, FIN-20520 Turku, Finland
关键词
EAE; environmental factors; MRI; multiple sclerosis; vitamin D;
D O I
10.1191/1352458505ms1157oa
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Past sun exposure and vitamin D supplementation have been associated with a reduction in the risk of MS. We measured the serum concentration of 25-hydroxyvitamin D (25[OH]D) at the time of MS diagnosis in 40 MS patients and 40 controls. We found no difference in the serum levels of 25(OH)D between MS patients and controls when all samples or samples obtained during winter months were compared, but MS patients had significantly lower serum 25(OH)D concentrations in June to September than the controls. The vitamin D stores were adequate for bone metabolism (>37 nmol/L) in 70% of MS patients throughout the year and within the hypovitaminosis level (<37 nmol/L) in 30% of MS patients at some time of the year During MS-relapses, 25(OH)D levels were lower than in remission, but mostly within the reference range observed in relation with normal bone metabolism. We conclude that the vitamin D stores in most MS patients are adequate for their normal bone metabolism. However lower vitamin D levels during MS relapses than in remission suggest that vitamin D could be involved in the regulation of the clinical disease activity of MS. The optimal serum levels of vitamin D for the regulation of immune responses remain to be determined.
引用
收藏
页码:266 / 271
页数:6
相关论文
共 33 条
  • [1] Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases
    Adorini, L
    Penna, G
    Giarratana, N
    Uskokovic, M
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 88 (02) : 227 - 233
  • [2] Auer DP, 2000, ANN NEUROL, V47, P276, DOI 10.1002/1531-8249(200002)47:2<276::AID-ANA28>3.0.CO
  • [3] 2-1
  • [4] BAUMGARTI HJ, 1991, DIABETES RES CLIN EX, V16, P145
  • [5] 1,25-dihydroxyvitamin D-3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis
    Cantorna, MT
    Hayes, CE
    DeLuca, HF
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) : 7861 - 7864
  • [6] Embry AF, 2000, ANN NEUROL, V48, P271, DOI 10.1002/1531-8249(200008)48:2<271::AID-ANA28>3.3.CO
  • [7] 2-F
  • [8] Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihydroxyvitamin D3 leads to early effects within the central nervous system
    Garcion, E
    Sindji, L
    Nataf, S
    Brachet, P
    Darcy, F
    Montero-Menei, CN
    [J]. ACTA NEUROPATHOLOGICA, 2003, 105 (05) : 438 - 448
  • [9] VITAMIN-D DEFICIENCY IN HOMEBOUND ELDERLY PERSONS
    GLOTH, FM
    GUNDBERG, CM
    HOLLIS, BW
    HADDAD, JG
    TOBIN, JD
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (21): : 1683 - 1686
  • [10] Hayes CE, 1997, P SOC EXP BIOL MED, V216, P21, DOI 10.3181/00379727-216-44153A